Clinical trial to evaluate the safety of Bortezomib combined with chemotherapy in children with refractory childhood acute lymphoblastic leukemia

Trial Profile

Clinical trial to evaluate the safety of Bortezomib combined with chemotherapy in children with refractory childhood acute lymphoblastic leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 May 2016

At a glance

  • Drugs Bortezomib (Primary) ; Antineoplastics
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 27 Apr 2013 New trial record
    • 18 Mar 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top